Clinical trial • Phase III • Neurology

MK-6916 for Acute pain | Chronic pain

Phase III trial of MK-6916 for Acute pain | Chronic pain. 54 participants.

Overview

Trial Therapeutic Area
Neurology
Trial Disease
Acute pain | Chronic pain
Trial Stage
Phase III

Key dates

Initial CTIS Submission Date
23-01-2026
First CTIS Authorization Date
02-03-2026

Trial design

Phase III trial across 1 site in Belgium.

Target Sample Size
54
Trial Duration For Participant
200

Eligibility

Recruits 54 Vulnerable population not selected; trial population: Healthy volunteers; no consent or assent handling information provided..

Vulnerable Population
Vulnerable population not selected; trial population: Healthy volunteers; no consent or assent handling information provided.

Recruitment

Planned Sample Size
54
Recruitment Window Months
6
Consent Approach
Informed consent to be obtained from adult healthy volunteers; no assent or minors consent information provided; no languages specified.

Geography

Total Number Of Sites
1
Total Number Of Participants
54

Belgium

Earliest CTIS Part Ii Submission Date
07-11-2025
Latest Decision Or Authorization Date
30-04-2026
Processing Time Days
174
Number Of Sites
1
Number Of Participants
54

Sites

Site Name
UZ Leuven
Department Name
Center for Clinical Pharmacology
Principal Investigator Name
Jan de Hoon
Principal Investigator Email
jan.dehoon@uzleuven.be
Contact Person Name
Jan de Hoon
Contact Person Email
jan.dehoon@uzleuven.be

Sponsor

Primary sponsor

Full Name
Merck Sharp & Dohme LLC
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Investigational products

Investigational Product Name
MK-6916

Related trials

Other published trials that may interest you.